Nvidia Falls in the Stock Market Today, November 9, as Its Board Opens an Investigation and Futures Rise
Stock futures rose on Monday after last week's AI selloff, CNBC reported. Nvidia fell 5.06% before the bell after its board opened an independent investigation into reports that its chief executive was the target of a foreign intelligence effort. The drop erased about $228 billion of its market value by 8:09 a.m. ET, yet the QQQ fund tracking the Nasdaq-100 still rose.
The short answer. Nvidia shares slid before Monday's open after its board said it is investigating reports that Jensen Huang, its chief executive, was the target of a foreign intelligence effort. The fall cost the company about $228 billion of market value, yet futures on the Dow, the S&P 500 and the Nasdaq 100 all rose, CNBC reported, which matters to anyone with an S&P 500 index fund, since Nvidia is one of the 500 stocks such funds hold. Elsewhere, Greenfire Resources and Vir Biotechnology jumped after company news, and Akamai fell after it proposed a $2.2 billion convertible note sale.
The market before the bell, Monday
Every company reporting the same week, with its date and time, is in StockTitan's Earnings Calendar for the Week of November 9, 2026.
On this page
Live updates
The newest update comes first, with the time it was written. Stock moves come from StockTitan's real-time data unless another source is named.
8:14 a.m. ET
Dow futures jump 1% as oil falls, and Nvidia trims its loss
Futures climbed further as oil prices fell. Dow futures were up 507 points, or 1%, and S&P 500 and Nasdaq 100 futures each rose 0.7%, CNBC reported in an update at 7:42 a.m. ET. CNBC tied the gain to cheaper oil. U.S. crude futures dropped to about $88 a barrel, it reported.
Nvidia was down 5.06% at 8:09 a.m. ET, a smaller fall than an hour earlier. At that price, the drop came to about $228 billion of market value. The QQQ fund that tracks the Nasdaq-100 was up 0.89% at 8:08 a.m. ET.
More stocks moved after company news. DoubleDown Interactive rose after its majority owner, DoubleU Games, announced an agreement for a cash tender offer of $16.25 for each American depositary share it does not own (DoubleDown release). Immunovant rose after its drug IMVT-1402 met the main goal of a rheumatoid arthritis trial (Immunovant release). Ionis Pharmaceuticals fell after it cut its 2026 sales forecast for its drug Tryngolza (Ionis release). Faeth Therapeutics fell after it reported early results from a mid-stage cancer trial (Faeth release). The table below gives each move.
7:09 a.m. ET
Nvidia slides on its board's investigation as Dow and Nasdaq futures rise
The week opened with futures higher and Nvidia lower. Dow futures were up 0.76% and Nasdaq 100 futures about 0.5%, CNBC reported in an update at 6:29 a.m. ET. Nvidia fell after its board opened an investigation into reports that its chief executive was the target of a foreign intelligence effort (NVIDIA board statement). Other chip stocks slipped too: Intel, Marvell, Qualcomm and Arm were each down more than 1%, CNBC reported in a story first published at 4:05 a.m. ET.
Overseas, Taiwan's main stock index closed up 4.94%, its biggest one-day gain since July 31, CNBC reported.
Smaller stocks moved beside their own news. Greenfire Resources rose after Strathcona Resources agreed to buy it (Strathcona release). Vir Biotechnology rose after a late-stage trial win (Vir release). Akamai fell after it proposed selling convertible notes, bonds that can later turn into shares (Akamai release). The table below gives each move.
Why is Nvidia stock down today
Nvidia shares fell before the open after its board said it is investigating reports about its chief executive, CNBC reported. The board said it has no reason to believe company secrets or national security were harmed, and that it still has confidence in him.
In a statement on Sunday at 3 p.m. ET, Nvidia's board said a committee of independent directors, helped by outside lawyers, will run the review. It follows recent reporting that Jensen Huang, the company's founder and chief executive, was the target of a foreign intelligence effort. The board said Huang supports the review and will cooperate with it (NVIDIA board statement).
Nvidia had 24.1 billion shares outstanding on August 21, its latest quarterly filing shows (NVIDIA 10-Q). At the 8:09 a.m. ET price, the morning's fall came to about $228 billion of market value.
The QQQ fund that tracks the Nasdaq-100 still rose before the bell, while other chip stocks slipped. Joachim Klement of Panmure Liberum told CNBC that the impact is currently contained to Nvidia. Nvidia will report its third-quarter results on November 17 and hold a call at 5 p.m. ET that day (Nvidia release).
Friday's session, when chip stocks bounced back after Thursday's selloff, is in StockTitan's November 6 market coverage.
Biggest stock movers today and why
The stocks below moved before the open beside their own company news. Greenfire Resources, DoubleDown Interactive, Immunovant and Vir Biotechnology rose. Ionis Pharmaceuticals, Faeth Therapeutics, Nvidia and Akamai fell.
| Company | Move | Company news |
|---|---|---|
| Greenfire Resources (GFR) | +38.16%, pre-market, 8:08 a.m. ET | Strathcona Resources agreed late on Sunday to buy the oil sands producer, offering each holder C$11.00 in cash or 0.25 Strathcona shares; the cash offer is 39% above Greenfire's November 6 close (release). |
| DoubleDown Interactive (DDI) | +17.44%, pre-market, 8:02 a.m. ET | Its majority owner, DoubleU Games, which holds about 67% of its shares, announced an agreement for a cash tender offer of $16.25 for each American depositary share it does not already own. These are the shares traded in the U.S. (release). |
| Immunovant (IMVT) | +11.37%, pre-market, 8:06 a.m. ET | The higher dose of its drug IMVT-1402 met the main goal of a trial in hard-to-treat rheumatoid arthritis that the company calls potentially registrational, meaning it may support an approval filing, and it plans to discuss next steps with the FDA later this year (release). |
| Vir Biotechnology (VIR) | +9.85%, pre-market, 8:09 a.m. ET | Its two-drug treatment for chronic hepatitis delta met the main goal of its phase 3 ECLIPSE 1 trial, and the company plans to file with the FDA in mid-2027 (release). |
| Ionis Pharmaceuticals (IONS) | -20.09%, pre-market, 8:08 a.m. ET | It cut its 2026 sales forecast for its drug Tryngolza to about $50 million, from a range of $100 million to $110 million, as the launch grew more slowly than it expected (release). |
| Faeth Therapeutics (FTH) | -18.37%, pre-market, 7:49 a.m. ET | It reported early results from a mid-stage trial of its combination of two oral drugs, given with chemotherapy, in advanced endometrial cancer: tumors shrank in 33% of the patients it could assess (release). |
| NVIDIA (NVDA) | -5.06%, pre-market, 8:09 a.m. ET | Its board opened an independent investigation after reports that chief executive Jensen Huang was the target of a foreign intelligence effort (release). |
| Akamai Technologies (AKAM) | -4.92%, pre-market, 8:07 a.m. ET | It proposed selling $2.2 billion of convertible notes due 2028 and 2031, partly to repay notes due in 2027 and to fund its cloud business (release). |
Source: StockTitan real-time Nasdaq data and StockTitan's pre-market movers board, against each stock's November 6 close; company releases linked in each row.
The Greenfire deal still needs two-thirds of the votes at both companies' shareholder meetings, a separate vote of the smaller holders, and court and competition approvals. Waterous Energy Fund, which owns 72% of Greenfire and 57% of Strathcona, has agreed to back it and take shares (Strathcona release).
At week 48 of Vir's trial, 44% of treated patients had both no detectable virus and normal liver enzyme levels, the trial's main goal. In the group whose treatment started later, none met that goal at week 12. Counting the virus alone, 79% of treated patients had none left that tests could detect (Vir release).
Akamai said it will buy hedges meant to limit how many new shares the notes create on conversion, and will sell warrants, which could add shares of their own (Akamai release).
What to watch for the rest of the day
The regular session opens at 9:30 a.m. ET. The week's big economic report, the consumer price index, comes on Tuesday.
- 10:00 a.m. ET: September wholesale inventories, CNBC reported.
- Today: Take-Two Interactive, Occidental Petroleum, KKR, Constellation Energy and Skydance report quarterly results, CNBC reported. Every company reporting this week is in StockTitan's Earnings Calendar for the Week of November 9, 2026.
- Tuesday, November 10, 8:30 a.m. ET: the consumer price index for October (BLS schedule), also on StockTitan's economic calendar.
- Tuesday, November 17, 5 p.m. ET: Nvidia's call on its third-quarter results (Nvidia release).
- January 2027: the Greenfire and Strathcona shareholder meetings on the deal, with closing expected shortly after (Strathcona release).
- First quarter of 2027: results of Vir's other two late-stage hepatitis delta trials, ECLIPSE 2 and ECLIPSE 3 (Vir release).
Our numbers
These figures are our calculations from the sources linked in this article.
- About $228 billion: Nvidia's market value lost before the bell, from the 24.1 billion shares on its latest 10-Q cover times the $9.44 fall from its November 6 close of $186.64 to its last trade at 8:09 a.m. ET in StockTitan real-time Nasdaq data.
Frequently asked questions
What is moving the stock market today?
Stock futures rose early on November 9 after last week's AI selloff, with Dow futures up 1% at 7:42 a.m. ET as oil prices fell, CNBC reported. Nvidia fell 5.06% by 8:09 a.m. ET after its board opened an investigation into reports that its chief executive was the target of a foreign intelligence effort.
Why is Nvidia (NVDA) stock down today?
Nvidia fell 5.06% before the bell by 8:09 a.m. ET on November 9. Its board opened an independent investigation after reports that chief executive Jensen Huang was the target of a foreign intelligence effort. The board said it has no reason to believe company secrets were compromised.
Why is Greenfire Resources (GFR) stock up today?
Greenfire rose 38.16% before the bell by 8:08 a.m. ET on November 9. Strathcona Resources agreed late on Sunday to buy it for C$11.00 in cash or 0.25 Strathcona shares per Greenfire share.
Why is Vir Biotechnology (VIR) stock up today?
Vir rose 9.85% before the bell by 8:09 a.m. ET on November 9. On Sunday it said its treatment for chronic hepatitis delta met the main goal of its phase 3 ECLIPSE 1 trial.
Why is DoubleDown Interactive (DDI) stock up today?
DoubleDown rose 17.44% before the bell by 8:02 a.m. ET on November 9. That morning its majority owner, DoubleU Games, announced an agreement for a cash tender offer of $16.25 for each American depositary share it does not own. These are the shares traded in the U.S.
Why is Ionis Pharmaceuticals (IONS) stock down today?
Ionis fell 20.09% before the bell by 8:08 a.m. ET on November 9. That morning it cut its 2026 sales forecast for its drug Tryngolza to about $50 million, from a range of $100 million to $110 million.
Sources
- StockTitan: live market coverage, November 6, 2026
- StockTitan: Earnings Calendar for the Week of November 9, 2026
- StockTitan economic calendar
- Statement from NVIDIA Board of Directors
- Strathcona Resources agreement to acquire Greenfire Resources release
- Vir Biotechnology ECLIPSE 1 phase 3 results release
- Akamai proposed convertible notes offering release
- DoubleU Games and DoubleDown Interactive tender offer agreement release
- Immunovant corporate updates and quarterly results release
- Ionis third quarter 2026 results release
- Faeth PIK-201 phase 2 topline results release
- NVIDIA third-quarter results conference call release
- NVIDIA quarterly report on Form 10-Q for the quarter ended July 26, 2026
- Bureau of Labor Statistics: Consumer Price Index release schedule
The information provided in this article is for educational and informational purposes only. It does not constitute financial advice, investment recommendation, or an endorsement of any particular investment strategy. Past performance does not guarantee future results. Investors should conduct their own research and consult with a qualified financial advisor before making investment decisions.